Sandoz Strikes US Settlements to Resolve Generic Drug Price Dispute
The deal would resolve remaining U.S. state claims and class actions, with $400 million paid over seven years and no admission of wrongdoing.
- On Monday, Sandoz agreed to pay $450 million to settle antitrust litigation with 43 U.S. states, resolving allegations that the generic drug manufacturer conspired with competitors to artificially inflate prices.
- Attorney General Jeff Jackson reached the settlement following years of investigations into suspected industry-wide price-fixing, alleging the company worked with competitors to discourage competition and raise profits.
- Sandoz will pay $400 million over seven years starting in 2027, plus $50 million to previously settling states, with the agreement containing no admission of wrongdoing by Sandoz Inc. or Fougera Pharmaceuticals.
- Separately, Sandoz finalized a $28.5 million agreement to resolve class-action litigation brought by indirect resellers, compensating retail pharmacies, hospitals, and clinics that purchased medicines during the alleged misconduct.
- These settlements resolve all pending U.S. federal and state governmental claims against the company, with ZKB analysts noting the agreement "brings clarity" to the legal dispute and "reduces potential risks for the future.
21 Articles
21 Articles
Tennessee, Others Obtain Settlement in Alleged Drug Price Fixing Scheme
Tennessee secured a settlement with a generic drug company over an alleged price-fixing scheme. A coalition of 43 states and territories announced a $400 million settlement to resolve allegations that Sandoz inflated its generic drug prices, limited competition, and restricted trade.
The Basel group saw its profit decline by 71% in the first half of the year. Monday, it announced that it had reached agreements to end complaints in the United States for more than 470 million dollars in a decade-old caseBy stopping at the profit published Wednesday by Sandoz for the first half of 2026, one might think that the Basel pharmaceutical group has lead in the wing. The specialist of generic and biosimilar medicines has seen its net p…
Connecticut Leads 43-Plaintiff Coalition In Securing $400M Settlement From Drug Provider
While Sandoz, Inc. did not admit to wrongdoing, it issued a statement announcing its commitment to paying the fee over the course of a seven-year period in order to clear its name of any federal and state allegations.
Sandoz agrees $450 mln settlement with 43 US states over antitrust claims
Swiss generic drugmaker Sandoz said on Monday that it has entered into a $450 million settlement agreement with 43 U.S. states and territories to resolve litigations concerning alleged anti-competitive conduct in the U.S. market for generic medicines.
Coverage Details
Bias Distribution
- 53% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
